BioCardia Unveils Groundbreaking Results in Phase III CardiAMP Cell Therapy for Heart Failure
BioCardia, Inc., a leader in biotechnological advancements for cardiovascular diseases, recently announced remarkable interim results from its Phase III CardiAMP® Cell Therapy trial for treating advanced chronic heart failure. These findings mark a significant milestone in the pursuit of innovative treatments for heart failure, showcasing the potential of stem cell therapy to revolutionize patient care. […]
The Dawn of a New Era in Heart Failure Treatment: BioCardia’s CardiAMP Heart Failure II Phase 3 Pivotal Study
In an exciting development for the field of cardiovascular medicine, BioCardia, Inc., a pioneering biotechnology company, has announced the activation of the CardiAMP Heart Failure II Phase 3 pivotal study. This groundbreaking study, recently greenlit by the FDA, represents a significant leap forward in the treatment of ischemic heart failure through advanced cell therapy techniques. […]
BioCardia Announces FDA Approval for Groundbreaking Heart Failure Treatment
BioCardia, Inc., a prominent player in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced a significant milestone. The U.S. Food and Drug Administration (FDA) has approved the Phase III clinical trial protocol for BioCardia’s CardiAMP autologous cell therapy. This therapy is designed for patients suffering from ischemic heart […]
Stem Cell Game-Changer: BioCardia Receives Patent for Innovative Therapeutic Approach
Sunnyvale, California-based BioCardia, Inc. [Nasdaq: BCDA], a company specializing in the development of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced on May 9, 2023, that the United States Patent Office has awarded them Patent Number 11,642,377. The patent, titled “Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells […]
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States Patent Office issued BioCardia Patent […]
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
SUNNYVALE, Calif., March 06, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces that detailed echocardiography data from the roll-in cohort of the Phase III CardiAMP® Cell Therapy Heart Failure Trial is being presented today at the American College of Cardiology annual meeting by […]
BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting
SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough CardiAMP® Cell Therapy for Heart Failure pivotal trial (ClinicalTrials.gov Identifier: NCT02438306) presented at the Heart Failure Society of America meeting in Washington, […]
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
SUNNYVALE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP® Cell Therapy Heart Failure Trial (clinicaltrials.gov Identifier: […]